Evidence map›Paper›PMID 35294730›Full record

ReviewCurrent cardiology reports2022

Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.

Mohammad Alkhalil, Vladimír Džavík, Deepak L Bhatt, Roxana Mehran, Shamir R Mehta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Mohammad AlkhalilDivision of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada.ORCID http://orcid.org/0000-0002-3088-8878
Vladimír DžavíkDivision of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada.
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
Roxana MehranIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Shamir R MehtaPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. smehta@mcmaster.ca.
Toronto General Hospital · CABrigham and Women's Hospital · USIcahn School of Medicine at Mount Sinai · USPopulation Health Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe evidence for use of dual antiplatelet therapy (DAPT) for patients undergoing percutaneous coronary intervention (PCI) in the elective setting is relatively sparse and is based on data from more than two decades ago. We will review the evidence supporting the use of DAPT with focus on stable patients undergoing elective PCI, including the role of potent P RECENT

findingsClopidogrel is the recommended P

Indexed as

Percutaneous Coronary InterventionAspirinClopidogrelDual Anti-Platelet TherapyHemorrhageHumansPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTreatment OutcomeAspirinClopidogrelPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsBleeding riskClopidogrelCoronary artery diseasePCIPrasugrelTicagrelor

Identifiers

PMID35294730
OpenAlexW4220765412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.